Loading…
H.R. 2821119th CongressPassed one chamberLatest action Jul 21, 2026Decoded by AI · checked against the record
The plain-language version leads. The official text is always the reference.
HR 2821 gives the FDA one year to update regulations so they officially reflect a 2022 law allowing non-animal drug testing methods.
50-second read · 4 questions answered below
HR 2821 requires the FDA to rewrite specific regulations within one year, replacing outdated "animal" testing language with the broader term "nonclinical testing." This aligns the FDA's actual rules with a 2022 law that already allows drug companies to use alternatives like lab-grown tissue models, organ-on-a-chip technology, or computer simulations. The bill also lets the FDA skip some standard public-comment procedures so the update can take effect immediately, and fixes a duplicate section label from prior law.
Pharmaceutical and biotech companies developing new drugs, plus researchers working on alternative testing methods, are directly affected. Patients could be indirectly affected through changes in how drug development timelines and testing options play out.
The mismatch between the 2022 law and outdated FDA regulations has created confusion over whether non-animal testing methods are truly permitted. Updating the rules removes that legal ambiguity and may also reduce the number of animals used in laboratory research.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: it passed the House, and the official record shows nothing new since. If the Senate changes it, it goes back to the House before reaching the President.
Latest action: — Received in the Senate.